What is Omniox?
Omniox is at the forefront of biotherapeutics, specializing in the development of its innovative H-NOX platform. This technology is engineered into first-in-class and best-in-class OMX oxygen delivery vehicles designed to address a spectrum of significant unmet medical needs. The company's core mission revolves around engineering biologics that safely deliver oxygen to hypoxic tissues. Abnormally low oxygen levels, or hypoxia, are a critical driver of disease pathology and exacerbate patient outcomes across various conditions. By precisely oxygenating pathologically hypoxic tissues, Omniox's OMX biologics aim to restore normal tissue function, offering the potential for improved patient prognoses and cures.
How much funding has Omniox raised?
Omniox has raised a total of $35.7M across 4 funding rounds:
Private Equity
$6.6M
Private Equity
$4.7M
Debt
$350K
Debt
$24.1M
Private Equity (2014): $6.6M, investors not publicly disclosed
Private Equity (2016): $4.7M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Debt (2026): $24.1M, investors not publicly disclosed
What's next for Omniox?
With the recent major strategic investment and substantial total capital raised, Omniox is poised for accelerated development and clinical progression. The enterprise-level funding suggests a robust validation of the H-NOX platform's therapeutic potential and the company's strategic direction. This capital infusion will likely fuel the advancement of its IND-stage pipeline, enabling further research, clinical trials, and regulatory submissions. The focus on oxygen delivery to hypoxic tissues positions Omniox to potentially disrupt treatment paradigms in areas with significant unmet medical needs, signaling a period of intensive growth and value creation.
See full Omniox company page
